SCHEMBL26698301

SCHEMBL26698301

CN1CCC(C(C(=O)O)c2ccccc2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM3 P20309 6/20 0.61
CACNA2D1 P54289 2/20 0.52
CACNA1B Q00975 2/20 0.52
CACNB1 Q02641 2/20 0.52
CACNA1C Q13936 2/20 0.52
CHRM1 P11229 2/20 0.50
CYP2D6 P10635 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
CHRM2 P08172 1/20 0.50
HTR1A P08908 1/20 0.50
ADRA2A P08913 1/20 0.50
DRD1 P21728 1/20 0.50
SLC6A2 P23975 1/20 0.50
ADRA1A P35348 1/20 0.50
OPRM1 P35372 1/20 0.50
DRD3 P35462 1/20 0.50
SLC6A3 Q01959 1/20 0.50
KCNH2 Q12809 1/20 0.50
HRH3 Q9Y5N1 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26698277 0.87 CHRM3 (0.58) CHRM3CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL66920 0.85 LMNA (0.54) CHRM3CYP2D6MEN1KMT2AMAPK1
Hydrochloric Acid SCHEMBL11359974 0.83 LMNA (0.53) CHRM3CYP2D6MEN1KMT2AKDM4E
SCHEMBL30771364 0.83 SLC6A2 (0.56) CHRM3CACNA2D1CACNA1BCACNB1CACNA1C
SCHEMBL28622389 0.82 HTR1E (0.65) CHRM3CHRM1CYP2D6MEN1KMT2A
SCHEMBL67619 0.82 HTR1E (0.60) CHRM3CHRM1CYP2D6MEN1KMT2A
SCHEMBL69127 0.82 HTR1E (0.65) CHRM3CHRM1CYP2D6MEN1KMT2A
SCHEMBL12531975 0.80 HTR1E (0.63) CHRM3CHRM1CYP2D6MEN1KMT2A
SCHEMBL67219 0.80 HTR1E (0.63) CHRM3CHRM1CYP2D6MEN1KMT2A
SCHEMBL3392214 0.79 CARM1 (0.63) CHRM3CACNA2D1CACNA1BCACNB1CACNA1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346616-A1 ROCK INHIBITORS AND USES THEREOF DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) 2025-11-13 US disclosed
EP-4532484-A1 ROCK INHIBITORS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2025-04-09 EP disclosed
CN-119173509-A ROCK inhibitors and uses thereof 迪哲(江苏)医药股份有限公司 2024-12-20 CN disclosed
WO-2023226965-A1 ROCK INHIBITORS AND USES THEREOF DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346616-A1 ROCK INHIBITORS AND USES THEREOF ROCK1, ROCK2, RHOA CHRM3 685/4885CACNA2D1 2505/4885CACNA1B 2760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.